Bright Minds Biosciences Inc
Veridion Score
Composite trend over time
Why is DRUG moving today?
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DRUG.
DRUG insider activity
Bright Minds Biosciences Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$9.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | 2026-04-28 | Cormorant Asset Management, LP | Insider | sell | $89.50 | 109,331 | 950,000 | $9.8M | SEC Form 4 |
DRUG contract awards, year to date.
Public federal awards linked to this ticker.
DRUG lobbying filings, year to date.
Registered lobbying filings matched to Bright Minds Biosciences Inc.